WuXi Biologics Clarifies Impact of US Bill, Stock Price Fluctuates, Business is Stable, CEO has no Military Background
In a recent announcement, WuXi Biotechnology Co., Ltd. addressed concerns regarding the potential impact of a draft bill proposed by the U.S. House of Representatives. The bill aims to restrict contracts with certain biotechnology suppliers, prompting fluctuations in the company’s stock price and trading volume.
However, WuXi Biologics emphasized that its business operations remain stable and are progressing according to annual and medium-term strategies. The management team expressed confidence in the company’s prospects and does not foresee any major adverse changes in its business and financial conditions.
Furthermore, the company clarified that its CEO and executive director, Dr. Chen Zhisheng, has no military background and has not worked for any institution with military connections. Additionally, the company stated that it does not engage in human genomics business and does not collect human genome data in its various operations.
WuXi Biologics also announced its intention to continue conducting share repurchases in accordance with previous announcements and cautioned shareholders and potential investors to exercise caution when buying or selling the company’s securities.
The financial community issued a warning, reminding individuals that the content, data, and tools in the announcement do not constitute investment advice and are for reference only. They emphasized the risks associated with the stock market and advised caution when investing.